Index of reports
> Cases with Anaemia (15)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to MS Contin (Morphine) where reactions include anaemia. The selected reports were submitted to the FDA during the sample period of about a year.
Possible MS Contin side effects in male
Reported by a physician from United States on 2012-06-29
Patient: male, weighing 67.1 kg (147.6 pounds)
Reactions: Atelectasis, Anaemia, Hypoxia, Sinus Tachycardia, Delirium, Thrombocytopenia
Drug(s) suspected as cause:
MS Contin
Dosage: 2 mg, unk
Administration route: Oral
Indication: Pain
Start date: 2012-04-01
Provenge
Dosage: 250 ml,unk
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
Dexamethasone Sodium Phosphate
Dosage: unk
Indication: Product Used FOR Unknown Indication
Other drugs received by patient: Multi-Vitamins; Digestive Enzymes; Leuprolide Acetate; Calcium Carbonate; Hydromorphone; Omeprazole; Vicodin
Possible MS Contin side effects in male
Reported by a pharmacist from United States on 2012-06-25
Patient: male, weighing 67.1 kg (147.6 pounds)
Reactions: Atelectasis, Anaemia, Hypoxia, Sinus Tachycardia, Delirium, Thrombocytopenia
Drug(s) suspected as cause:
MS Contin
Dosage: 2 mg, unk
Administration route: Oral
Indication: Pain
Start date: 2012-04-01
Provenge
Indication: Prostate Cancer Metastatic
Dexamethasone
Indication: Product Used FOR Unknown Indication
Provenge
Dosage: 250 ml, unk
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
Other drugs received by patient: Calcium Carbonate; Digestive Enzymes; Hydromorphone HCL; Leuprolide Acetate; Multivitamin / 00097801 /; Vicodin; Omeprazole
Possible MS Contin side effects in 66 year old male
Reported by a physician from United States on 2012-06-18
Patient: 66 year old male, weighing 67.0 kg (147.4 pounds)
Reactions: Atelectasis, Back Pain, Anaemia, Hyperglycaemia, General Physical Health Deterioration, Lymphangiosis Carcinomatosa, Delirium, Arthralgia, Thrombocytopenia, Metastases To Central Nervous System, Sinus Tachycardia, Asthenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
MS Contin
Administration route: Oral
Indication: Pain
Decadron
Administration route: Oral
Provenge
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
Other drugs received by patient: Calcium Carbonate; Digestive Enzymes; Vitamins (Unspecified); Vicodin; Omeprazole; Hydromorphone; Lupron
Possible MS Contin side effects in male
Reported by a physician from United States on 2012-06-15
Patient: male, weighing 67.1 kg (147.6 pounds)
Reactions: Atelectasis, Anaemia, Hypoxia, Sinus Tachycardia, Thrombocytopenia, Delirium
Drug(s) suspected as cause:
Digestive Enzymes
Dosage: unk
Provenge
Dosage: 250 ml, unk
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
MS Contin
Dosage: 2 mg, unk
Administration route: Oral
Indication: Pain
Dexamethasone Sodium Phosphate Ophthalmic Solution,0.1%
Dosage: unk
Other drugs received by patient: Multi-Vitamins; Calcium Carbonate; Omeprazole; Leuprolide Acetate; Vicodin; Hydromorphone
Possible MS Contin side effects in male
Reported by a physician from United States on 2012-06-14
Patient: male, weighing 67.1 kg (147.6 pounds)
Reactions: Atelectasis, Anaemia, Hypoxia, Delirium, Sinus Tachycardia, Thrombocytopenia
Drug(s) suspected as cause:
MS Contin
Dosage: 2 mg, unk
Administration route: Oral
Indication: Pain
Digestive Enzymes
Dosage: unk
Provenge
Dosage: 250 ml, unk
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
Hydromorphone
Dexamethasone Sodium Phosphate
Dosage: unk
Other drugs received by patient: Leuprolide Acetate; Calcium Carbonate; Vicodin; Multi-Vitamins; Omeprazole
Possible MS Contin side effects in male
Reported by a physician from United States on 2012-06-05
Patient: male, weighing 67.1 kg (147.6 pounds)
Reactions: Atelectasis, Anaemia, Hypoxia, Delirium, Thrombocytopenia, Sinus Tachycardia
Drug(s) suspected as cause:
Provenge
Dosage: 250 ml, unk
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
MS Contin
Dosage: 2 mg, unk
Administration route: Oral
Indication: Pain
Dexamethasone
Indication: Product Used FOR Unknown Indication
Provenge
Indication: Prostate Cancer Metastatic
Digestive Enzymes
Other drugs received by patient: Multivitamin / 00097801 /; Calcium Carbonate; Leuprolide Acetate; Vicodin; Omeprazole
Possible MS Contin side effects in 66 year old male
Reported by a physician from United States on 2012-06-04
Patient: 66 year old male, weighing 67.0 kg (147.4 pounds)
Reactions: Back Pain, Atelectasis, Anaemia, Hyperglycaemia, General Physical Health Deterioration, Lymphangiosis Carcinomatosa, Delirium, Arthralgia, Thrombocytopenia, Asthenia, Metastases To Central Nervous System, Sinus Tachycardia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
MS Contin
Administration route: Oral
Indication: Pain
Decadron
Administration route: Oral
Provenge
Indication: Prostate Cancer
Start date: 2012-03-29
End date: 2012-03-29
Other drugs received by patient: Vitamins (Unspecified); Digestive Enzymes; Calcium Carbonate; Lupron; Vicodin; Omeprazole; Hydromorphone
Possible MS Contin side effects in 66 year old male
Reported by a physician from United States on 2012-05-16
Patient: 66 year old male, weighing 67.1 kg (147.6 pounds)
Reactions: Atelectasis, Abasia, Disorientation, Hypoxia, Thrombocytopenia, Back Pain, Anaemia, Hyperglycaemia, General Physical Health Deterioration, Muscular Weakness, Lymphangiosis Carcinomatosa, Delirium, Arthralgia, Sinus Tachycardia, Asthenia, Metastases To Central Nervous System
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Provenge
Dosage: 250 ml, single, intravenous
Indication: Prostate Cancer Metastatic
Start date: 2012-03-29
End date: 2012-03-29
MS Contin
Dosage: 2 mg, prn, oral
Administration route: Oral
Indication: Inadequate Analgesia
Start date: 2012-03-29
End date: 2012-03-29
MS Contin
Dosage: 2 mg, prn, oral
Administration route: Oral
Indication: Pain
Start date: 2012-03-29
End date: 2012-03-29
Other drugs received by patient: Lupron; Digestive Enzymes (Betaine Hydrochloride, Bromelains, Cellulase, Pancr; Multivitamin (Ascorbi Acid, Calcium Pantotyhenate, Ergocalciferol, NIC; Calcium Carbonate; Vicodin; Omeprazole
Possible MS Contin side effects in 40 year old male
Reported by a physician from Hungary on 2011-12-08
Patient: 40 year old male
Reactions: Weight Decreased, Jaundice, Anaemia, Hypotension, Coma, Neoplasm Progression, Disorientation, Hepatic Enzyme Increased, Convulsion, Therapeutic Response Decreased, Urinary Retention, Hallucination
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Morphine
Indication: Cancer Pain
MS Contin
Administration route: Oral
Fentanyl-100
End date: 2010-10-01
MS Contin
Administration route: Oral
Indication: Cancer Pain
Fentanyl-100
End date: 2010-04-01
Fentanyl-100
Fentanyl-100
Nsaid
Indication: Pain
MS Contin
Administration route: Oral
Amitriptyline HCL
Indication: Pain
MS Contin
Administration route: Oral
Hydromorphone HCL
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
Fentanyl-100
Indication: Cancer Pain
Fentanyl-100
Start date: 2010-06-01
Gemcitabine
Indication: Chemotherapy
Cisplatin
Indication: Chemotherapy
Possible MS Contin side effects in 40 year old male
Reported by a physician from Hungary on 2011-11-18
Patient: 40 year old male
Reactions: Jaundice, Weight Decreased, Hypotension, Anaemia, Neoplasm Progression, Coma, Disorientation, Hepatic Enzyme Increased, Convulsion, Therapeutic Response Decreased, Urinary Retention, Hallucination
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Hydromorphone HCL
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
Fentanyl-100
Gemcitabine
Indication: Chemotherapy
Cisplatin
Indication: Chemotherapy
Fentanyl-100
Indication: Cancer Pain
Fentanyl-100
End date: 2010-10-01
Morphine
Indication: Cancer Pain
Amitriptyline HCL
Indication: Pain
Nsaid
Indication: Pain
MS Contin
Administration route: Oral
MS Contin
Administration route: Oral
Fentanyl-100
Fentanyl-100
Start date: 2010-06-01
MS Contin
Administration route: Oral
Fentanyl-100
End date: 2010-04-01
MS Contin
Administration route: Oral
Indication: Cancer Pain
Possible MS Contin side effects in 40 year old male
Reported by a physician from Hungary on 2011-11-14
Patient: 40 year old male
Reactions: Weight Decreased, Jaundice, Hypotension, Anaemia, Neoplasm Progression, Coma, Disorientation, Convulsion, Hepatic Enzyme Increased, Therapeutic Response Decreased, Urinary Retention, Hallucination
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cisplatin
Indication: Chemotherapy
MS Contin
Administration route: Oral
Fentanyl
Start date: 2010-06-01
Gemcitabine
Indication: Chemotherapy
Fentanyl
End date: 2010-04-01
Fentanyl
Fentanyl
Morphine
Indication: Cancer Pain
Fentanyl
Indication: Cancer Pain
MS Contin
Administration route: Oral
Hydromorphone HCL
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
Fentanyl
End date: 2010-10-01
Amitriptyline HCL
Indication: Pain
Nsaid
Indication: Pain
MS Contin
Administration route: Oral
Indication: Cancer Pain
MS Contin
Administration route: Oral
Possible MS Contin side effects in 40 year old male
Reported by a physician from Hungary on 2011-11-08
Patient: 40 year old male
Reactions: Weight Decreased, Jaundice, Anaemia, Hypotension, Coma, Neoplasm Progression, Disorientation, Convulsion, Hepatic Enzyme Increased, Therapeutic Response Decreased, Urinary Retention, Hallucination
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Fentanyl-100
Start date: 2010-06-01
Fentanyl-100
Fentanyl-100
End date: 2010-04-01
MS Contin
Administration route: Oral
MS Contin
Administration route: Oral
Indication: Cancer Pain
Gemcitabine
Indication: Chemotherapy
Fentanyl-100
Amitriptyline HCL
Indication: Pain
Cisplatin
Indication: Chemotherapy
Hydromorphone HCL
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
MS Contin
Administration route: Oral
Nsaid
Indication: Pain
MS Contin
Administration route: Oral
Fentanyl-100
Indication: Cancer Pain
Fentanyl-100
End date: 2010-10-01
Morphine
Indication: Cancer Pain
Possible MS Contin side effects in 40 year old male
Reported by a physician from Hungary on 2011-11-07
Patient: 40 year old male
Reactions: Weight Decreased, Jaundice, Hypotension, Anaemia, Neoplasm Progression, Coma, Disorientation, Hepatic Enzyme Increased, Convulsion, Therapeutic Response Decreased, Urinary Retention, Hallucination
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
MS Contin
Administration route: Oral
MS Contin
Administration route: Oral
Amitriptyline HCL
Indication: Pain
Cisplatin
Indication: Chemotherapy
Fentanyl
Fentanyl
Indication: Cancer Pain
Fentanyl
Nsaid
Indication: Pain
MS Contin
Administration route: Oral
Indication: Cancer Pain
Fentanyl
End date: 2010-04-01
Fentanyl
Start date: 2010-06-01
Hydromorphone HCL
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
Morphine
Indication: Cancer Pain
MS Contin
Administration route: Oral
Gemcitabine
Indication: Chemotherapy
Fentanyl
End date: 2010-10-01
Possible MS Contin side effects in 40 year old male
Reported by a physician from Hungary on 2011-10-19
Patient: 40 year old male
Reactions: Jaundice, Weight Decreased, Anaemia, Hypotension, Coma, Neoplasm Progression, Disorientation, Hepatic Enzyme Increased, Convulsion, Therapeutic Response Decreased, Urinary Retention, Hallucination
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Fentanyl
Cisplatin
Indication: Chemotherapy
Amitriptyline HCL
Indication: Pain
Morphine
Indication: Cancer Pain
MS Contin
Administration route: Oral
Hydromorphone HCL
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
Fentanyl
Indication: Cancer Pain
Fentanyl
End date: 2010-10-01
Fentanyl
Fentanyl
End date: 2010-04-01
Fentanyl
Start date: 2010-06-01
Nsaid
Indication: Pain
MS Contin
Administration route: Oral
Indication: Cancer Pain
MS Contin
Administration route: Oral
MS Contin
Administration route: Oral
Gemcitabine Hydrochloride
Indication: Chemotherapy
Possible MS Contin side effects in 39 year old male
Reported by a physician from United States on 2011-10-10
Patient: 39 year old male
Reactions: Weight Decreased, Confusional State, Bile Duct Obstruction, Drug Effect Decreased, Dysphagia, Anaemia, Hypotension, General Physical Health Deterioration, Neoplasm Progression, Somnolence, Malaise, Cholangitis, Urinary Retention, Hallucination, Muscle Spasms
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Exalgo
Dosage: 32 mg, unk
Indication: Cancer Pain
Start date: 2010-04-01
End date: 2010-06-01
Morphine
Dosage: 20 mg, single
Indication: Pain
Start date: 2010-01-01
End date: 2010-01-01
Fentanyl-100
Dosage: 125 ug/hr, unk
Start date: 2010-06-01
End date: 2010-01-01
Fentanyl-100
Dosage: 150 ug/hr, unk
Start date: 2010-01-01
Fentanyl-100
Dosage: 200 ug/hr, unk
Start date: 2010-01-01
End date: 2010-01-01
Gemcitabine Hydrochloride
Dosage: 3 series of 8 treatments
Indication: Chemotherapy
Start date: 2010-04-01
End date: 2010-07-01
Nsaid's
Dosage: prn pain
Indication: Pain
FEM Protocol
Dosage: 2 series
Start date: 2010-01-01
Fentanyl-100
Dosage: 50 ug/hr, unk
Indication: Cancer Pain
Fentanyl-100
Dosage: unk
Start date: 2010-01-01
End date: 2010-01-01
Fentanyl-100
Dosage: 100 ug/hr, unk
Start date: 2010-01-01
End date: 2010-01-01
Nsaid's
Dosage: regularly administered
Cisplatin
Dosage: 3 series of 8 treatments
Indication: Chemotherapy
Start date: 2010-04-01
End date: 2010-07-01
MS Contin
Dosage: 3 x130 mg
Administration route: Oral
Indication: Cancer Pain
Start date: 2010-10-01
Fentanyl-100
Dosage: 75 ug/hr, unk
End date: 2010-04-01
Fentanyl-100
Dosage: 250 ug/hr, unk
Start date: 2010-01-01
End date: 2010-10-01
MS Contin
Dosage: 3 x 190 mg
Administration route: Oral
End date: 2010-01-01
MS Contin
Dosage: 2 x 90 mg
Administration route: Oral
Start date: 2010-01-01
Morphine Sulfate
Dosage: unk
Indication: Breakthrough Pain
Start date: 2010-01-01
Amitriptyline HCL
Dosage: 2 x 1
Indication: Pain
Other drugs received by patient: Proton Pump Inhibitors
|